argenx (ARGX) Stock Forecast & Price Target

Argenx's stock outlook is positively impacted by the rapid adoption of its pre-filled syringe formulation for Vyvgart, which has resulted in approximately 1,000 prescribers as of Q2, including 150 new prescribers, indicating significant market expansion potential. The company reported remarkable topline growth, with Q1 revenue reaching $790 million (up 98% year-over-year) and Q2 revenue at $949 million (up 97% year-over-year), driven by increased use in generalized myasthenia gravis (gMG) and encouraging traction in chronic inflammatory demyelinating polyneuropathy (CIDP), with over 2,500 CIDP patients on therapy. Furthermore, with ongoing advancements in clinical studies, including promising results from the Phase Ib DOK7-CMS study and plans for a Phase III trial in 2026, Argenx is well-positioned for continued growth through product label expansions and innovation in its pipeline of therapies.

Argenx faces several risks that contribute to a negative outlook on its stock, including potential lower-than-expected growth in sales of its lead product, Vyvgart, coupled with the possibility of unforeseen safety issues arising during ongoing clinical trials for efgartigimod and empasiprubart. Additionally, the emergence of new competitors and macroeconomic factors, such as inflation and foreign exchange fluctuations, could adversely affect the company's financial performance and market position. As projected penetration rates for Vyvgart in the chronic inflammatory demyelinating polyneuropathy (CIDP) patient population remain modest, these combined factors may hinder the company's overall growth trajectory and profitability prospects.